Hansen's Disease (Leprosy) - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Hansen's Disease (Leprosy) – Comprehensive Medical Guide

Hansen's Disease (Leprosy) – Comprehensive Medical Guide

Overview

Hansen’s disease, commonly known as leprosy, is a chronic infectious disease caused by the bacterium Mycobacterium leprae (or the closely related M. ulcerans). The organism primarily affects the skin, peripheral nerves, mucous membranes of the upper respiratory tract, and the eyes.

Although historically feared and stigmatized, leprosy is now a treatable condition with a > global prevalence of less than 200,000 cases reported in 2022, down from the > ~ 3 million cases recorded before the introduction of multidrug therapy (MDT) in the 1980s (WHO, 2023). Most cases occur in low‑ and middle‑income countries, especially in South‑East Asia (India accounts for ~ 60 % of new cases), Brazil, and parts of sub‑Saharan Africa.

Leprosy can affect anyone, but certain groups have a higher risk: people with prolonged close contact with untreated patients, those with compromised immune systems, and individuals living in overcrowded or impoverished settings where sanitation is limited.

Symptoms

Symptoms develop slowly, often over years, and can be classified into two major clinical forms—**paucibacillary (PB)** (few bacteria, mild disease) and **multibacillary (MB)** (many bacteria, more severe disease). The main manifestations include:

Skin Lesions

  • Hypopigmented or reddish patches – lighter or reddish‑brown areas that may be slightly raised, flat, or nodular.
  • Sensory loss – diminished ability to feel touch, temperature, or pain within the patch; patients may not notice burns or injuries.
  • Hair loss (alopecia) and dryness – lesions often become dry and lose hair.
  • Nodules or plaques – especially in MB disease, lesions can be thickened, raised, and may ulcerate.

Neurologic Involvement

  • Peripheral nerve thickening – nerves become enlarged (e.g., ulnar, peroneal, posterior tibial). Palpable nodules may be felt under the skin.
  • Loss of sensation – especially in the hands, feet, and around the eyes, leading to accidental injuries.
  • Muscle weakness – weakness of the intrinsic hand muscles or foot dorsiflexors, causing claw‑hand or foot drop.

Eye Problems

  • Dryness, redness, and reduced blinking; corneal ulceration can develop if facial nerves are damaged.

Other Signs

  • Enlarged lymph nodes (rare).
  • Loss of eyebrows (especially the lateral third) – a classic but not universal sign.

Symptoms may appear anywhere from 6 months to 20 years after exposure; most patients notice gradual numbness or a persistent skin patch before seeking care.

Causes and Risk Factors

Etiology

Leprosy is caused by infection with *Mycobacterium leprae* or *M. ulcerans*. The bacteria are acid‑fast, slow‑growing organisms that thrive at cooler body temperatures (30–33 °C), which explains their predilection for skin and peripheral nerves.

Transmission

  • Primarily via respiratory droplets from the nose and mouth of an untreated patient.
  • Prolonged close contact (e.g., household members) increases risk.
  • Skin-to-skin contact is less important, but lesions can harbor bacilli.
  • Animal reservoirs (e.g., armadillos in the southern United States) can transmit *M. leprae* to humans through bites or handling.

Risk Factors

  • Living in endemic areas (India, Brazil, Indonesia, Nigeria, Philippines).
  • Close, repeated exposure to an untreated leprosy patient.
  • Immunosuppression (HIV, diabetes, chronic steroid use).
  • Genetic susceptibility – certain HLA types (e.g., HLA‑DR2) are associated with higher risk.
  • Poverty, overcrowding, and poor nutrition, which can impair immune response.

Diagnosis

Early diagnosis is essential to prevent nerve damage and disability. A combination of clinical assessment and laboratory testing is used.

Clinical Evaluation

  • Detailed history focusing on skin changes, numbness, exposure to known cases, and travel.
  • Physical exam looking for characteristic lesions, nerve thickening, and sensory deficits.

Laboratory Tests

  • Skin smear (slit‑skin smear) – samples taken from multiple sites are stained (Ziehl‑Neelsen) to detect acid‑fast bacilli. Quantified as a bacterial index (BI, 0–6).
  • Skin biopsy – histopathology reveals granulomas, nerve involvement, and acid‑fast organisms; used when smear is negative.
  • Polymerase chain reaction (PCR) – highly sensitive for detecting *M. leprae* DNA, especially in paucibacillary cases.
  • Serologic tests (e.g., anti‑PGL‑1 antibody) – supportive but not diagnostic because antibodies can persist after cure.

Classification for Treatment

The WHO classifies leprosy based on the number of skin lesions and bacillary load:

  • Paucibacillary (PB): 1–5 lesions, negative skin smear.
  • Multibacillary (MB): >5 lesions or positive skin smear.

Treatment Options

Since the early 1980s, leprosy has been curable with multidrug therapy (MDT). Treatment is provided free of charge by the WHO in endemic countries.

Standard MDT Regimens

FormDrugs (monthly dose)Duration
Paucibacillary (≤5 lesions) Rifampicin 600 mg + Dapsone 100 mg 6 months
Multibacillary (>5 lesions) Rifampicin 600 mg + Dapsone 100 mg + Clofazimine 300 mg 12 months (WHO recommendation; 24 months in some programs)

Additional Medications

  • Clofazimine – has anti‑inflammatory effect; may cause skin discoloration.
  • Prednisone or other steroids – used for acute nerve inflammation (reversal reactions) to preserve function.
  • Thalidomide – reserved for severe erythema nodosum leprosum (ENL) reactions, under strict monitoring due to teratogenicity.

Management of Reactions

  • Type 1 (reversal) reaction: sudden increase in inflammation of existing lesions; treat with high‑dose steroids (e.g., prednisone 1 mg/kg) tapering over weeks.
  • Type 2 (ENL) reaction: painful nodules, fever, and systemic symptoms; treat with thalidomide or high‑dose steroids, plus continuation of MDT.

Lifelong Follow‑up

  • Regular skin and nerve exams for at least 2 years after completion of MDT.
  • Physiotherapy and orthotic devices for patients with residual nerve damage.
  • Psychosocial support to address stigma.

Living with Hansen's Disease (Leprosy)

With effective treatment, most patients achieve cure and can lead normal lives. Practical tips:

  • Medication adherence – take the full course of MDT even if symptoms improve.
  • Skin care – keep lesions clean and moisturized; use gentle soaps; protect areas with reduced sensation from burns and cuts.
  • Foot care – inspect feet daily, wear well‑fitting shoes, treat minor injuries promptly to avoid ulcers.
  • Eye protection – use lubricating eye drops if facial nerves are involved; cover eyes while sleeping if blinking is impaired.
  • Physiotherapy – exercises to maintain muscle strength and range of motion, especially after nerve involvement.
  • Nutrition – balanced diet rich in protein, vitamins A, C, D, and zinc supports immune recovery.
  • Social support – engage with community groups, counseling, or leprosy self‑help organizations to reduce isolation.
  • Legal rights – many countries have legislation prohibiting discrimination based on leprosy status.

Prevention

  • Early detection & treatment – the most effective way to stop transmission.
  • Contact prophylaxis – a single dose of rifampicin given to close contacts reduces their risk by ~ 60 % (WHO, 2021).
  • Improved living conditions – reducing crowding, enhancing ventilation, and ensuring adequate nutrition.
  • Education – community programs that dispel myths and encourage people to seek care promptly.
  • Animal control – avoiding handling or consuming armadillos in endemic regions.

Complications

If left untreated or if nerve damage is not managed, leprosy can lead to permanent disability:

  • Peripheral neuropathy → loss of sensation, repeated injuries, ulceration, secondary infection.
  • Claw hand or foot drop due to motor nerve involvement.
  • Ocular complications – corneal ulcer, cataract, blindness.
  • Severe skin infections (e.g., cellulitis) and chronic ulceration.
  • Stigma‑related mental health issues: depression, anxiety, social withdrawal.

When to Seek Emergency Care

Call emergency services (e.g., 911) or go to the nearest emergency department if you notice:
  • Sudden, severe pain in a hand or foot with rapid swelling (possible acute neuritis).
  • Fever, chills, and a rapidly enlarging red nodule (possible severe ENL reaction).
  • Vision loss, sudden eye pain, or a white spot on the cornea.
  • Signs of infection at a skin lesion – increasing redness, warmth, pus, or foul odor.
Prompt treatment can prevent permanent nerve damage and preserve function.

References

1. World Health Organization. Global leprosy (Hansen disease) update, 2023. https://www.who.int/news-room/fact-sheets/detail/leprosy
2. Mayo Clinic. Leprosy (Hansen disease). https://www.mayoclinic.org/diseases-conditions/leprosy
3. CDC. Leprosy (Hansen Disease) – General Information. https://www.cdc.gov/leprosy/
4. National Institute of Allergy and Infectious Diseases (NIAID). Mycobacterium leprae. https://www.niaid.nih.gov/diseases-conditions/leprosy
5. Cleveland Clinic. Leprosy (Hansen Disease) Treatment. https://my.clevelandclinic.org/health/diseases/17175-leprosy-hansen-disease

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References